BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee CM, Lee DH, Ahn BK, Hwang JJ, Yoon H, Shin CM, Park YS, Kim N. Protective Effect of Proton Pump Inhibitor for Survival in Patients with Gastroesophageal Reflux Disease and Idiopathic Pulmonary Fibrosis. J Neurogastroenterol Motil 2016;22:444-51. [PMID: 26932897 DOI: 10.5056/jnm15192] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Ghisa M, Marinelli C, Savarino V, Savarino E. Idiopathic pulmonary fibrosis and GERD: links and risks. Ther Clin Risk Manag 2019;15:1081-93. [PMID: 31564886 DOI: 10.2147/TCRM.S184291] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
2 Fidler L, Sitzer N, Shapera S, Shah PS. Treatment of Gastroesophageal Reflux in Patients With Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Chest 2018;153:1405-15. [PMID: 29559309 DOI: 10.1016/j.chest.2018.03.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
3 Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, Kreuter M, Lynch DA, Maher TM, Martinez FJ, Molina-Molina M, Myers JL, Nicholson AG, Ryerson CJ, Strek ME, Troy LK, Wijsenbeek M, Mammen MJ, Hossain T, Bissell BD, Herman DD, Hon SM, Kheir F, Khor YH, Macrea M, Antoniou KM, Bouros D, Buendia-Roldan I, Caro F, Crestani B, Ho L, Morisset J, Olson AL, Podolanczuk A, Poletti V, Selman M, Ewing T, Jones S, Knight SL, Ghazipura M, Wilson KC. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2022;205:e18-47. [PMID: 35486072 DOI: 10.1164/rccm.202202-0399ST] [Reference Citation Analysis]
4 Somogyi V, Chaudhuri N, Torrisi SE, Kahn N, Müller V, Kreuter M. The therapy of idiopathic pulmonary fibrosis: what is next? Eur Respir Rev 2019;28:190021. [PMID: 31484664 DOI: 10.1183/16000617.0021-2019] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 16.7] [Reference Citation Analysis]
5 Targownik LE, Fisher DA, Saini SD. AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review. Gastroenterology 2022:S0016-5085(21)04083-X. [PMID: 35183361 DOI: 10.1053/j.gastro.2021.12.247] [Reference Citation Analysis]
6 Moua T, Lee AS, Ryu JH. Comparing effectiveness of prognostic tests in idiopathic pulmonary fibrosis. Expert Rev Respir Med 2019;13:993-1004. [PMID: 31405303 DOI: 10.1080/17476348.2019.1656069] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
7 Tran T, Suissa S. The effect of anti-acid therapy on survival in idiopathic pulmonary fibrosis: a methodological review of observational studies. Eur Respir J 2018;51:1800376. [PMID: 29724921 DOI: 10.1183/13993003.00376-2018] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
8 Liu Y, Nepali K, Liou J. Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets. J Med Chem 2017;60:527-53. [DOI: 10.1021/acs.jmedchem.6b00935] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 9.0] [Reference Citation Analysis]
9 Ebrahimpour A, Wang M, Li L, Jegga AG, Bonnen MD, Eissa NT, Raghu G, Jyothula S, Kheradmand F, Hanania NA, Rosas IO, Ghebre YT. Esomeprazole attenuates inflammatory and fibrotic response in lung cells through the MAPK/Nrf2/HO1 pathway. J Inflamm (Lond) 2021;18:17. [PMID: 34011367 DOI: 10.1186/s12950-021-00284-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Singh S, Sharma BB, Bairwa M, Gothi D, Desai U, Joshi JM, Talwar D, Singh A, Dhar R, Sharma A, Ahluwalia B, Mangal DK, Jain NK, Pilania K, Hadda V, Koul PA, Luhadia SK, Swarnkar R, Gaur SN, Ghoshal AG, Nene A, Jindal A, Jankharia B, Ravindran C, Choudhary D, Behera D, Christopher DJ, Khilnani GC, Samaria JK, Singh H, Gupta KB, Pilania M, Gupta ML, Misra N, Singh N, Gupta PR, Chhajed PN, Kumar R, Chawla R, Jenaw RK, Chawla R, Guleria R, Agarwal R, Narsimhan R, Katiyar S, Mehta S, Dhooria S, Chowdhury SR, Jindal SK, Katiyar SK, Chaudhri S, Gupta N, Singh S, Kant S, Udwadia Z, Singh V, Raghu G. Management of interstitial lung diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP). Lung India 2020;37:359-78. [PMID: 32643655 DOI: 10.4103/lungindia.lungindia_275_20] [Reference Citation Analysis]
11 Savarino E, Zentilin P, Marabotto E, Savarino V. Pathophysiological Studies Are Mandatory to Understand the Benefit of Proton Pump Inhibitors in Patients with Idiopathic Pulmonary Fibrosis. J Neurogastroenterol Motil. 2016;22:710-711. [PMID: 27572930 DOI: 10.5056/jnm16120] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Jo HE, Corte TJ, Glaspole I, Grainge C, Hopkins PMA, Moodley Y, Reynolds PN, Chapman S, Walters EH, Zappala C, Allan H, Keir GJ, Cooper WA, Mahar AM, Ellis S, Macansh S, Goh NS. Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry. BMC Pulm Med 2019;19:84. [PMID: 31053121 DOI: 10.1186/s12890-019-0846-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
13 Patrucco F, Venezia L, Nicali R, Pellicano R, Bellan M, Balbo PE. Idiopathic pulmonary fibrosis and gastroesophageal reflux. Minerva Pneumol 2020;59. [DOI: 10.23736/s0026-4954.20.01865-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Lee YS, Jang BH, Ko SG, Chae Y. Comorbid risks of psychological disorders and gastroesophageal reflux disorder using the national health insurance service-National Sample Cohort: A STROBE-compliant article. Medicine (Baltimore) 2018;97:e0153. [PMID: 29718833 DOI: 10.1097/MD.0000000000010153] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Kishaba T. Evaluation and management of Idiopathic Pulmonary Fibrosis. Respir Investig 2019;57:300-11. [PMID: 30853366 DOI: 10.1016/j.resinv.2019.02.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
16 Tran T, Suissa S. Comparing New-User Cohort Designs: The Example of Proton Pump Inhibitor Effectiveness in Idiopathic Pulmonary Fibrosis. Am J Epidemiol 2021;190:928-38. [PMID: 33124647 DOI: 10.1093/aje/kwaa242] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Morrow LE, Hilleman D, Malesker MA. Management of patients with fibrosing interstitial lung diseases. Am J Health Syst Pharm 2021:zxab375. [PMID: 34608488 DOI: 10.1093/ajhp/zxab375] [Reference Citation Analysis]
18 Ntolios P, Tzilas V, Bouros E, Avdoula E, Karakasiliotis I, Bouros D, Steiropoulos P. The Role of Microbiome and Virome in Idiopathic Pulmonary Fibrosis. Biomedicines 2021;9:442. [PMID: 33924195 DOI: 10.3390/biomedicines9040442] [Reference Citation Analysis]
19 Solopov P, Colunga Biancatelli RML, Dimitropoulou C, Catravas JD. Sex-Related Differences in Murine Models of Chemically Induced Pulmonary Fibrosis. Int J Mol Sci 2021;22:5909. [PMID: 34072833 DOI: 10.3390/ijms22115909] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
20 Ghebre YT. Proton Pump Inhibitors in IPF: A Call for Clinical Trials. Front Pharmacol 2018;9:499. [PMID: 29867501 DOI: 10.3389/fphar.2018.00499] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
21 Khor YH, Bissell B, Ghazipura M, Herman D, Hon SM, Hossain T, Kheir F, Knight SL, Kreuter M, Macrea M, J Mammen M, Molina-Molina M, Selman M, Wijsenbeek M, Raghu G, Wilson KC. Antacid Medication and Antireflux Surgery in Patients with Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Ann Am Thorac Soc 2022;19:833-44. [PMID: 35486080 DOI: 10.1513/AnnalsATS.202102-172OC] [Reference Citation Analysis]
22 Tran T, Assayag D, Ernst P, Suissa S. Effectiveness of Proton Pump Inhibitors in Idiopathic Pulmonary Fibrosis: A Population-Based Cohort Study. Chest 2021;159:673-82. [PMID: 32882251 DOI: 10.1016/j.chest.2020.08.2080] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
23 McDonnell MJ, Hunt EB, Ward C, Pearson JP, O'Toole D, Laffey JG, Murphy DM, Rutherford RM. Current therapies for gastro-oesophageal reflux in the setting of chronic lung disease: state of the art review. ERJ Open Res 2020;6:00190-2019. [PMID: 33693049 DOI: 10.1183/23120541.00190-2019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Akiyama J, Kuribayashi S, Baeg MK, Bortoli N, Valitova E, Savarino EV, Kusano M, Triadafilopoulos G. Current and future perspectives in the management of gastroesophageal reflux disease. Ann N Y Acad Sci 2018;1434:70-83. [DOI: 10.1111/nyas.13850] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]